Fitbit is having a bad week.
On Tuesday, the maker of fitness trackers premiered a smartwatch, the Blaze. Shortly after, the company’s shares tumbled, ending the day down 18%.
Such technology is found in its Charge HR and Surge devices, as well as the newly announced Blaze. Essentially, Fitbit uses LED lights to monitor blood flow through a user’s wrist and, by using algorithms, can determine a user’s heart rate. Similar technology is used in the Apple Watch, along with several more competing smartwatches and fitness trackers.
According to the suit, three different plaintiffs said they bought Fitbit devices based off the company’s advertised promise that it accurately tracked heart rates. Fitbit’s advertising materials often contain phrases such as “every beat counts” and “know your heart” in relation the heart monitoring technology.
One participant in the suit had a trainer manually count her heart rate during a workout. Her trainer recorded a heart rate of 160 beats per minute (bpm) while her Fitbit Charge HR indicated her heart rate was only 82 beats per minute, according to the filing. Two other plaintiffs are mentioned in the suit, each citing similar experiences with a Fitbit PurePulse-equipped product.
The suit goes on to say that a cardiologist, who used an electrocardiogram machine to compare results, found Fitbit’s heart rate sensor consistently reported inaccurate results. With a heart rate of 110 bpm or higher, the suit states the Fitbit devices often failed to record a heart rate at all. When a heart rate was captured, the reading was off by an average of 24.34 bpm, the suit said.
When contacted by Fortune, Fitbit provided the following comment:
Fitbit’s shares were down nearly 6% in mid-day trading at $22.86.
- The Fall of Roe and the Failure of the Feminist Industrial Complex
- The Ocean Is Climate Change’s First Victim and Last Resort
- Column: 6 Proven Ways to Reduce Gun Violence
- Ads Are Officially Coming to Netflix. Here's What That Means for You
- Jenny Slate on the Unifying Power of a Well-Heeled Shell Named Marcel
- Column: The FDA's Juul Ban May Not be a Pure Public Health Triumph
- What the Supreme Court’s Abortion Decision Means for Your State